CAS No. :	69-05-6
Formula :	C₂₃H₃₂Cl₃N₃O
M.W :	472.88
SMILES Code :	CC(NC1=C(C=C(OC)C=C2)C2=NC3=CC(Cl)=CC=C31)CCCN(CC)CC.Cl.Cl
Synonyms :	Mepacrine dihydrochloride; SN-390 dihydrochloride; Quinacrine 2HCl
MDL No. :	MFCD00012659
InChI Key :	UDKVBVICMUEIKS-UHFFFAOYSA-N
Pubchem ID :	6239

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

4C8 mouse glioma cells	0.8 µM	10 hours	To evaluate the effect of quinacrine on autophagy and apoptosis in 4C8 glioma cells. Results showed that quinacrine induced LC3-II accumulation under both normoxic and hypoxic conditions, indicating increased autophagic vacuoles.	Neuro Oncol. 2013 Dec;15(12):1673-83
Primary rat cortical neurons	2 µM	16 to 24 hours	To investigate the dissociation effect of quinacrine on Aβ aggregates and its protective effect on synaptic function. Results showed that quinacrine treatment significantly reduced Aβ-induced neuronal cell death and synaptic dysfunction.	Sci Rep. 2021 Jun 8;11(1):12043
4C8 mouse glioma cells	2.5 µM	24 hours	To assess the effect of quinacrine on autophagic vacuole formation in 4C8 glioma cells. Fluorescence microscopy revealed punctate RFP-LC3 distribution in quinacrine-treated cells, indicating increased autophagic vacuoles.	Neuro Oncol. 2013 Dec;15(12):1673-83
Lung cancer H1299 cells	7 µM and 10 µM	24 hours	FER overexpression confers resistance to quinacrine	Proc Natl Acad Sci U S A. 2011 May 10;108(19):7968-73
Candida albicans clinical isolates (ATCC 10231, ATCC 14053, ATCC 24433, 42379, 53264)	4 to 2048 μg/mL	24 hours	Quinacrine showed activity against both mature biofilms and biofilm formation for all tested clinical isolates.	Antimicrob Agents Chemother. 2014 Dec;58(12):7501-9
Candida albicans SC5314	4 to 2048 μg/mL	24 hours	Evaluate the inhibitory effect of quinacrine on mature biofilms, results showed quinacrine significantly reduced biofilm metabolic activity at concentrations ≥128 μg/ml.	Antimicrob Agents Chemother. 2014 Dec;58(12):7501-9
SARS-CoV-2 3CLpro	0-150 µM	30 minutes	Quinacrine showed competitive inhibition against SARS-CoV-2 3CLpro with an IC50 value of 7.8±0.6 µM.	Viruses. 2021 May 10;13(5):873
GBM-I neurospheres	5.43 µM (IC50)	48 hours	Evaluate the inhibitory effect of SI113 combined with Quinacrine on the growth of GBM-I neurospheres, showing a synergistic effect.	J Exp Clin Cancer Res. 2019 May 17;38(1):202
GBM3-Luc neurospheres	4.79 µM (IC50)	48 hours	Evaluate the inhibitory effect of SI113 combined with Quinacrine on the growth of GBM3-Luc neurospheres, showing a synergistic effect.	J Exp Clin Cancer Res. 2019 May 17;38(1):202
T98G glioblastoma cells	2.18 µM (IC50)	48 hours	Evaluate the inhibitory effect of SI113 combined with Quinacrine on the growth of T98G cells, showing a synergistic effect.	J Exp Clin Cancer Res. 2019 May 17;38(1):202
U373MG glioblastoma cells	2.39 µM (IC50)	48 hours	Evaluate the inhibitory effect of SI113 combined with Quinacrine on the growth of U373MG cells, showing a synergistic effect.	J Exp Clin Cancer Res. 2019 May 17;38(1):202
ADF human glioblastoma cells	2.46 µM (IC50)	48 hours	Evaluate the inhibitory effect of SI113 combined with Quinacrine on the growth of ADF cells, showing a synergistic effect.	J Exp Clin Cancer Res. 2019 May 17;38(1):202
Human colon cancer RKO cells	10 µM	48 hours	To screen for quinacrine-resistant cell lines and found that overexpression of FER tyrosine kinase confers resistance	Proc Natl Acad Sci U S A. 2011 May 10;108(19):7968-73
Vero E6 cells	0-30 µM	48 hours	Evaluate the inhibitory effect of Quinacrine on SARS-CoV-2 viral replication, results showed that Quinacrine significantly reduces viral replication and virus cytotoxicity.	Viruses. 2021 Jan 17;13(1):121
RKM+ cells	1 µM	6 days	To assess the effect of quinacrine on mouse PrPSc accumulation, results showed more than threefold reduction in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
SMB cells	1 µM	6 days	To assess the effect of quinacrine on mouse PrPSc accumulation, results showed 5- to 14-fold reductions in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
ScN2a cells	1 µM	6 days	To assess the effect of quinacrine on mouse PrPSc accumulation, results showed 5- to 14-fold reductions in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
Elk21+ cells	1 µM	6 days	To assess the effect of quinacrine on CWD PrPSc accumulation, results showed more than twofold increase in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
Elk21+ cells	1 µM	60 days	To assess the long-term effect of quinacrine on CWD PrPSc accumulation, results showed approximately sevenfold increase in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
4C8 mouse glioma cells	2 µM	72 hours	To evaluate the effect of quinacrine on apoptosis in 4C8 glioma cells. Results showed that combined quinacrine and cediranib treatment under hypoxic conditions significantly increased cleaved caspase-3 expression.	Neuro Oncol. 2013 Dec;15(12):1673-83
RKD+ cells	1 µM	8 passages	To assess the effect of quinacrine on deer PrPSc accumulation, results showed more than twofold increase in PrPSc levels	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33

Male Sprague Dawley rats	Cisplatin-induced nephrotoxicity model	Intraperitoneal injection	10 mg/kg/day	Once daily for 10 days	Quinacrine ameliorates cisplatin-induced renal toxicity via upregulating SIRT-1, downregulating inflammatory markers (ICAM-1 and TNF-α), reducing oxidative stress, and inhibiting apoptosis.	Int J Mol Sci. 2021 Oct 1;22(19):10660
5XFAD transgenic mice	Alzheimer’s disease model	Intravenous injection	2 mg/kg	Once a week for 6 weeks	To evaluate the dissociation effect of quinacrine on Aβ plaques and its impact on AD-related protein expression. Results showed that quinacrine significantly reduced the number and size of Aβ plaques and decreased astrocytosis.	Sci Rep. 2021 Jun 8;11(1):12043
Human	Patients with sporadic CJD	Oral	200-600 mg/day	Once daily for 2-8 weeks	To evaluate the safety and efficacy of quinacrine combined with a P-glycoprotein inhibitor in treating Creutzfeldt-Jakob disease. Results showed that low-dose quinacrine combined with verapamil improved clinical symptoms without liver dysfunction or hematological toxicity.	Cell Mol Neurobiol. 2004 Dec;24(6):873-5
Transgenic mice	CWD infection model	Oral	30 mg/kg/day	Daily administration until terminal disease signs	To assess the effect of quinacrine on CWD disease progression, results showed no significant effect on disease onset time or PrPSc accumulation	Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6028-33
CD1 mice	RML prion infection model	Oral	40 mg/kg/day	Once daily for 43-60 days	Combination of quinacrine with γ-secretase inhibitor reduced PrPSc by ≈95% in the neocortex and hippocampus and ≈50% in the thalamus, and prevented dendritic atrophy and loss.	Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10595-600
C57BL/6×DBA/2F1 hybrid mice	Intracranial 4C8 mouse glioma model	Oral gavage	50 mg/kg	Daily until the end of the experiment	To evaluate the antivascular and antitumor efficacy of quinacrine in intracranial glioma. Results showed that quinacrine alone had no significant effect on tumor growth or survival, but combined with cediranib significantly reduced tumor growth (>2-fold) and increased median survival (>2-fold).	Neuro Oncol. 2013 Dec;15(12):1673-83

NCT00574483	Renal Cell Carcinoma	Phase 2	Withdrawn(reevaluation of comp... More >>ound development) Less <<	January 2008	United States, New York ... More >> Community Care Physicians Albany, New York, United States, 12208 United States, North Carolina ClinWorks Cancer Research Center Charlotte, North Carolina, United States, 28207 Less <<
NCT00183092	-		Completed	-	-
NCT00183092	Creutzfeldt-Jakob Disease	Phase 2	Completed	-	United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94143 Less <<
NCT00104663	Prion Disease	Not Applicable	Completed	-	United Kingdom ... More >> National Prion Clinic London, United Kingdom, WC1N 3BG Less <<
NCT00417274	Prostatic Cancer	Phase 2	Completed	-	-
NCT01844076	Colorectal Adenocarcinoma	Phase 1 Phase 2	Recruiting	June 2020	United States, Pennsylvania ... More >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19011 Contact: Wafik El-Deiry 215-214-4233 Principal Investigator: Wafik S. El-Deiry, MD Less <<
NCT01839955	Recurrent Non-small Cell Lung ... More >>Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Less <<	Phase 1	Completed	-	United States, Ohio ... More >> University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Cleveland, Ohio, United States, 44106 Less <<
NCT00417274	-		Completed	-	-

{[proInfo.proName]}

CAS No.: 69-05-6

{[proInfo.proName]}

CAS No.: 69-05-6

Alternative Products

Product Details of Quinacrine 2HCl

Safety of Quinacrine 2HCl

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed